Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAPPHIRE: Suprachoroidal CLS-TA + Aflibercept in RVO
NCT02980874Phase 3Terminated
- Sponsor
- Clearside Biomedical
- Start
- Jan 2017
- Primary completion
- Dec 2018
- Modality
- Orthosteric Ligands
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial of triamcinolone in retinal vein occlusion (RVO) and macular edema (2 arms), sponsored by Clearside Biomedical. Primary endpoint: Proportion of Subjects Demonstrating ≥ 15 Letter Improvement From Baseline in Early Treatment of Diabetic Retinopathy Study (ETDRS) BCVA at 2 months. Started Jan 2017; status: terminated.
02
Drugs
triamcinolone
03
Conditions
retinal vein occlusion (RVO)macular edema
Beyond the preview
Go deeper on NCT02980874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02980874.